Biotech | March 01, 2022
AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Subscribe To Our Newsletter & Stay Updated
